Data Programs
Harnessing the Power of Data to Advance Cancer Immunotherapy
Data is more than information —
it’s the engine driving discovery
At the Cancer Research Institute (CRI), we unite world-class scientists, cutting-edge technology, and advanced analytics to transform how cancer is understood and treated. CRI equips researchers with the training, tools, and data they need to connect insights across genomics, imaging, and other biological datasets, driving discovery and improving patient outcomes. Every piece of information — from raw patient samples to AI-ready biological data — moves us closer to a world immune to cancer.
Stories, Events, & Collaborations
Data programs are a massive opportunity for CRI, to really drive forward the collection of meaningful biologically relevant drug perturbation data of the immune system.
Ansu Satpathy, MD, PhD
Stanford University,
CRI Lloyd J. Old STAR
Funded Data Programs
CRI’s Data Programs bridge research and real-world impact, advancing the technologies, tools, and collaborations that turn information into innovation.
CRI Bioinformatics Bootcamp
CRI’s Bioinformatics Bootcamp trains early-career researchers to analyze high-dimensional biological data. Through hands-on instruction in sequencing, imaging, and computational analysis, participants gain highly sought after practical skills to translate complex datasets into new immunotherapy insights.
Partners: Memorial Sloan Kettering Cancer Center; University of California, Los Angeles; Washington University in St. Louis
CRI Immuno-Informatics Postdoctoral Fellowship
This fellowship supports early-career scientists developing dual expertise in immunology and data science to drive innovation in cancer immunotherapy. By training researchers to bridge biology and computation, the program accelerates discoveries that deepen our understanding of the immune system and advance new immune-based treatments.
Meet a 2025 Awardee: Samira Ghazali, PhD, Harvard Medical School
CRI iAtlas
CRI iAtlas is an interactive web platform for exploring tumor-immune interactions using harmonized genomic, transcriptomic, and clinical datasets. It enables researchers to uncover relationships between immune context and treatment outcomes, advancing precision immuno-oncology.
Partners: Institute for Systems Biology; Sage Bionetworks; UNC Lineberger Comprehensive Cancer Center
ImmGen (Immunological Genome Project)
ImmGen is a collaborative consortium of immunology and computational biology labs mapping how the genome regulates immune cell function in mice. By defining gene-expression programs and regulatory networks, it provides an open, foundational resource for understanding immune system regulation.
2025 Awardee: Harvard Medical School
Publications
Sharing Knowledge. Accelerating Discovery.
Open access and collaboration are essential to advancing cancer research. Through peer-reviewed studies, landscape analyses, and global task-force reports, CRI shares data and insights that drive innovation in immunotherapy. By making our findings widely available, we aim to help scientists, clinicians, and partners worldwide turn discovery into impact.
Peer-reviewed publications
Our research appears in high-impact journals, including Nature Reviews Drug Discovery, The Lancet Oncology, Cell, Immunity, and more.
RECENT PUBLICATIONS
- Cancer Cell Therapies: Global clinical trial trends and emerging directions
Nature Reviews Drug Discovery, November 2025 - The emerging landscape of engineered bacteria cancer therapies
Nature Biotechnology, April 2025 - Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies
Frontiers in Immunology, May 2024 - The changing landscape of cancer cell therapies: clinical trials and real-world data
Nature Reviews Drug Discovery, May 2024 - PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
Nature Reviews Drug Discovery, November 2023 - Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors
Nature Reviews Drug Discovery, April 2023
PAST PUBLICATIONS
- Population diversity in immuno-oncology trials
Nature Reviews Drug Discovery, November 2022 - Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Nature Reviews Drug Discovery, November 2022 - Landscape of cancer cell therapies: trends and real-world data
Nature Reviews Drug Discovery, June 2022 - Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Nature Reviews Drug Discovery, February 2022 - The clinical pipeline for cancer cell therapies
Nature Reviews Drug Discovery, June 2021 - COVID-19 impact on oncology clinical trials: a 1-year analysis
Nature Reviews Drug Discovery, May 2021 - Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer
Clinical Oncology: Case Report, March 2021 - CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
The Lancet Oncology, January 2021 - Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
Nature Reviews Drug Discovery, November 2020 - Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Cell, October 2020 - Immuno-oncology drug development forges on despite COVID-19
Nature Reviews Drug Discovery, September 2020 - Cancer cell therapies: the clinical trial landscape
Nature Reviews Drug Discovery, May 2020 - Impact of COVID-19 on oncology clinical trials
Nature Reviews Drug Discovery, May 2020 - Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Journal for ImmunoTherapy of Cancer, April 2020 - Trends in clinical development of PD-1/PD-L1 inhibitors
Nature Reviews Drug Discovery, November 2019 - Immuno-oncology drug development goes global
Nature Reviews Drug Discovery, September 2019 - The global pipeline of cell therapies for cancer
Nature Reviews Drug Discovery, May 2019 - Immunotherapy and targeted therapy combinations in metastatic breast cancer
The Lancet Oncology, March 2019 - The clinical trial landscape for PD1/L1 immune checkpoint inhibitors
Nature Reviews Drug Discovery, November 2018 - Trends in the global immuno-oncology landscape
Nature Reviews Drug Discovery, October 2018 - Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
Annals of Oncology, November 2018 - The global landscape of cancer cell therapy
Nature Reviews Drug Discovery, May 2018 - Comprehensive analysis of the clinical immuno-oncology landscape
Annals of Oncology, January 2018 - A Blueprint to Advance Colorectal Cancer Immunotherapies
Cancer Immunology Research, November 2017 - Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference
Cancer Immunology Research, December 2016 - De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
Cancer Immunology Research, April 2016 - Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference
Cancer Immunology Research, January 2016 - T cell assays and MIATA: the essential minimum for maximum impact
Immunity, July 2012 - The Cancer Vaccine Collaborative: a new model of coordinated discovery
Cancer Immunology Research, May 2012 - A methodological framework to enhance the clinical success of cancer immunotherapy
Nature Biotechnology, October 2011 - Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
Cancer Immunology Immunotherapy, January 2011
White papers
Our white papers distill complex research into clear, evidence-based insights for clinicians, researchers, and decision-makers.
AI has the potential to transform all three steps of drug discovery – target identification, drug generation, and patient selection.
Marc Tessier-Lavigne, PhD
CEO of Xaira Therapeutics,
2025 CRI Panelist
Transforming Data into Cures
CRI’s data ecosystem thrives on collaboration — from researchers who generate insights to donors who make them possible. Help us accelerate the next breakthroughs in cancer immunotherapy. Together, we can make data matter more — transforming information into cures.
